Entropy Neurodynamics Limited has released a press release.
Appendix 4D and Half Year Report for period 31 Dec 2024
Filed with ASX ·
6ix hasn’t read this filing yet.
Entropy Neurodynamics Limited on 6ix
Story so far
Earlier from Entropy Neurodynamics
- Positive interim results in Phase 2a TRP-8802 IBS trial
- Phase 1b extension results meet study objectives
- Phase 1b determines optimal parameters for TRP-8803 use
- $6m funding to fast track TRP-8803 clinical trial strategy
- Pause in Trading
Later from Entropy Neurodynamics
- TRP-8803 BED trial to commence with Swinburne this quarter
- Binge Eating Disorder Trial receives Human Ethics approval
- Patient recruitment for world first TRP-8803 trial underway
- $2.6m in non-dilutive capital funding secured
- Landmark EEG Biomarker Agreement for Precision Psychiatry
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics